September 10, 2021 - IBA Acquisition of own shares

Corporate
/
10.09.2021

IBA – ACQUISITION OF OWN SHARES

 

Immediate Release – September 10th, 2021

 

Louvain-la-Neuve, Belgium, September 10th, 2021 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on June 29th, 2021.

 

Under this program, IBA has requested a financial intermediary to repurchase up to 250.000 IBA ordinary shares on its behalf under the terms of a discretionary mandate agreement with validity until December 30th, 2021, effective as from June 30th, 2021, to cover the company’s obligations under a long term incentive plan for certain members of its personnel.

 

In the framework of this share buyback program, IBA repurchased 3.145 IBA shares on Euronext Brussels in the period from September 3rd, 2021 up to and including September 9th, 2021, as follows:

 

 

The total number of shares purchased under this program therefore amounts to 174.145. As a result, the current situation with respect to treasury shares (held directly by IBA SA and indirectly through its subsidiary IBA Investments SCRL) is the following:

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

 

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at www.iba-worldwide.com

 

 

 

Contact person

IBA

Christian Matton,

Chief Legal Officer

shareholderrelations@iba-group.com

Share
Download

Cookies policy

En poursuivant votre navigation sur ce site, vous acceptez l’utilisation de cookies pour vous proposer des services et des offres adaptés à vos centres d’intérêts.

Gérer vos préférences de cookies

Chez IBA, le respect de votre vie privée reste une priorité.

Les cookies fonctionnels garantissent le fonctionnement du site web. Ils ne peuvent pas être désactivés. En réglant vos préférences, vous pouvez activer et désactiver l’utilisation de ces cookies sur notre site web. Ces réglages ne seront valides que sur l’appareil que vous utilisez actuellement.

Cookies policies